5-MeO-PiPT

5-Methoxy-N-propyl-N-isopropyltryptamine (5-MeO-PiPT) is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a 5-HT1A and 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 89% (vs 5-HT), and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.